证券日报网讯海特生物（300683）9月24日在互动平台回答投资者提问时表示，截至9月19日公司股东人 数为15，886户。 ...

证券日报网讯海特生物（300683）9月11日在互动平台回答投资者提问时表示，截至9月10日公司股东人 数为15530户。 ...

Company Overview - Hite Bio is located in Wuhan Economic and Technological Development Zone, established on April 8, 1992, and listed on August 8, 2017. The company focuses on the research, production, and sales of innovative biopharmaceuticals, as well as providing small molecule chemical pharmaceutical research and contract drug manufacturing services [1][2]. Financial Performance - For the first half of 2025, Hite Bio reported revenue of 275 million yuan, a year-on-year decrease of 3.36%. The net profit attributable to the parent company was -39.18 million yuan, reflecting a significant year-on-year decline of 72.10% [2]. - The company has distributed a total of 85.23 million yuan in dividends since its A-share listing, with 17.02 million yuan distributed over the past three years [3]. Stock Performance - As of September 9, Hite Bio's stock price was 40.83 yuan per share, with a market capitalization of 5.344 billion yuan. The stock has increased by 72.21% year-to-date but has seen a decline of 9.31% over the last five trading days and 19.12% over the last 20 days [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent appearance on July 23 [1]. Shareholder Information - As of August 29, Hite Bio had 14,600 shareholders, an increase of 8.86% from the previous period. The average number of tradable shares per shareholder was 8,349, which decreased by 8.14% [2]. Business Segments - The main revenue sources for Hite Bio include technical service income (57.20%), injectable mouse nerve growth factor (25.59%), and injectable Epoetin (17.04%), with other income contributing 0.17% [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing, and is involved in various concept sectors such as traditional Chinese medicine, raw materials, small-cap stocks, mergers and acquisitions, and the Hubei Free Trade Zone [2].

国投证券股份有限公司关于 武汉海特生物制药股份有限公司持续督导工作 2025 年半年度定期现场检查报告 2、查阅大额资金往来的交易合同等资料； 1 | 2、是否在股票上市后 个月内建立内部审计制度并设立内 6 | | √ | | --- | --- | --- | | 部审计部门（如适用） | | | | 3、内部审计部门和审计委员会的人员构成是否合规（如适 | √ | | | 用） | | | | 4、审计委员会是否至少每季度召开一次会议，审议内部审 | √ | | | 计部门提交的工作计划和报告等（如适用） | | | | 5、审计委员会是否至少每季度向董事会报告一次内部审计 | √ | | | 工作进度、质量及发现的重大问题等（如适用） | | | | 6、内部审计部门是否至少每季度向审计委员会报告一次内 | | | | 部审计工作计划的执行情况以及内部审计工作中发现的问 | √ | | | 题等（如适用） | | | | 7、内部审计部门是否至少每季度对募集资金的存放与使用 | √ | | | 情况进行一次审计（如适用） | | | | 8、内部审计部门是否在每个会计年度结束前二个月内向审 | √ | ...

2025年半年度持续督导跟踪报告 国投证券股份有限公司 关于武汉海特生物制药股份有限公司 | 保荐机构名称：国投证券股份有限公司 | 被保荐公司简称：海特生物 | | --- | --- | | 保荐代表人姓名：孙素淑 | 联系电话：021-55518389 | | 保荐代表人姓名：燕云 | 联系电话：021-35082978 | 一、保荐工作概述 2 | 1.信息披露 | 无 | 不适用 | | --- | --- | --- | | 2.公司内部制度的建立和 | 无 | 不适用 | | 执行 | | | | 3．"三会"运作 | 无 | 不适用 | | 4.控股股东及实际控制人 | 无 | 不适用 | | 变动 | | | | 5.募集资金存放及使用 | 无 | 不适用 | | 6.关联交易 | 无 | 不适用 | | 7.对外担保 | 无 | 不适用 | | 8.收购、出售资产 | 无 | 不适用 | | 9.其他业务类别重要事项 | | | | （包括对外投资、风险投 | 无 | 不适用 | | 资、委托理财、财务资助、 | | | | 套期保值等） | | | | 10．发行人或者其聘请的中 | | ...

Market Overview - The Shanghai Composite Index closed at 3875.53 points, with a change of 0.46% [1] - The total trading volume of A-shares reached 27,776.47 billion yuan [1] Technical Analysis - A total of 63 A-shares experienced a "death cross" where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Haitai Biological: 5-day MA at 50.56 yuan, 10-day MA at 51.97 yuan, a difference of -2.72% [1] - Titan Technology: 5-day MA at 27.25 yuan, 10-day MA at 27.85 yuan, a difference of -2.16% [1] - Anglikang: 5-day MA at 50.17 yuan, 10-day MA at 51.27 yuan, a difference of -2.15% [1] Individual Stock Performance - Haitai Biological: Today's change of -2.67%, with a turnover rate of 8.82% [1] - Titan Technology: Today's change of -2.29%, with a turnover rate of 4.22% [1] - Anglikang: Today's change of -0.85%, with a turnover rate of 6.98% [1] - Other stocks with notable performance include: - Rainbow Group: Today's change of -0.13%, with a turnover rate of 3.47% [1] - Wanli Stone: Today's change of -0.51%, with a turnover rate of 2.18% [1] Additional Observations - The market shows a trend of declining stock prices for several companies, indicating potential bearish sentiment [1][2] - The analysis of moving averages suggests a cautious approach for investors focusing on these stocks [1][2]

Market Overview - The Shanghai Composite Index is at 3864.71 points with a change of 0.18% [1] - The total trading volume of A-shares is 138.21 billion yuan [1] Technical Analysis - 62 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Haitai Biological: 5-day MA is -2.28% below the 10-day MA [1] - Titan Technology: 5-day MA is -2.07% below the 10-day MA [1] - Anglikang: 5-day MA is -1.88% below the 10-day MA [1] Individual Stock Performance - Haitai Biological (300683): Today's change is +1.95%, with a 5-day MA of 51.01 yuan and a 10-day MA of 52.20 yuan [1] - Titan Technology (688133): Today's change is -1.41%, with a 5-day MA of 27.30 yuan and a 10-day MA of 27.88 yuan [1] - Anglikang (002940): Today's change is +1.84%, with a 5-day MA of 50.44 yuan and a 10-day MA of 51.40 yuan [1] - Other stocks with notable performance include: - Rainbow Group (300314): +0.04% change, 5-day MA of 23.44 yuan [1] - Wanli Stone (002785): -0.89% change, 5-day MA of 29.62 yuan [1] Summary of Stocks with Death Cross - A list of stocks experiencing a death cross includes: - Haitai Biological, Titan Technology, Anglikang, and others with varying degrees of percentage differences between their moving averages [1][2]

武汉海特生物制药股份有限公司（以下简称"公司"）于近日取得湖北省药 品监督管理局换发的《药品生产许可证》，同意《药品生产许可证》的变更申请。 本次新增栓剂生产范围及栓剂生产线，并对替硝唑栓的生产地址进行了变更，其 他内容不变。变更后的《药品生产许可证》具体内容如下： 一、《药品生产许可证》基本情况 企业名称：武汉海特生物制药股份有限公司 注册地址：武汉经济技术开发区海特科技园 社会信用代码：91420100724667038L 法定代表人：陈亚 证券代码：300683 证券简称：海特生物 公告编号：2025-039 武汉海特生物制药股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 分类码：AshCh 本次新增栓剂生产范围及栓剂生产线，并对替硝唑栓的生产地址进行了变更， 以上变更对公司业绩无重大影响，敬请广大投资者理性投资，注意投资风险。 生产地址和生产范围：1.湖北省武汉经济技术开发区海特科技园 治疗用生 物制品（注射用抗乙型肝炎转移因子、注射用鼠神经生长因子、注射用埃普奈明）、 冻干粉针剂、散剂、小容量注射剂、片 ...

Group 1 - The A-share market's innovative drug concept stocks have experienced a collective decline for the third consecutive day, with notable drops including Nanjing New Pharmaceutical falling over 11% and Yuandong Bio down over 9% [2] - Other companies such as Borui Pharmaceutical, Zhaoyan New Drug, and Kangyuan Pharmaceutical also saw declines exceeding 6%, while Shutaishen, Hite Bio, Shouyao Holdings, and Wanbangde dropped over 5% [2] Group 2 - The MACD golden cross signal has formed, indicating a positive trend for certain stocks [3]

Market Overview - On August 27, the medical services sector declined by 2.14%, with Haitai Biological leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Stock Performance - Notable gainers in the medical services sector included: - Digital Human: Closed at 17.23, up 12.84% with a trading volume of 200,800 shares and a turnover of 355 million [1] - Nanmo Biology: Closed at 62.11, up 8.34% with a trading volume of 41,300 shares and a turnover of 250 million [1] - Dian Diagnostics: Closed at 17.49, up 5.81% with a trading volume of 813,500 shares and a turnover of 1.467 billion [1] - Major decliners included: - Haitai Biological: Closed at 51.28, down 6.87% with a trading volume of 128,800 shares and a turnover of 684 million [2] - Hongbo Pharmaceutical: Closed at 37.93, down 5.79% with a trading volume of 125,600 shares and a turnover of 498 million [2] - Huacheng Medical: Closed at 3.78, down 5.74% with a trading volume of 843,900 shares and a turnover of 328 million [2] Capital Flow - The medical services sector experienced a net outflow of 1.677 billion from institutional investors, while retail investors saw a net inflow of 951 million [2][3] - Key stocks with significant capital flow included: - Jinyu Medical: Net inflow of 120 million from institutional investors, but a net outflow of 79 million from retail investors [3] - Huada Gene: Net inflow of 107 million from institutional investors, with outflows from both retail and speculative investors [3] - Dian Diagnostics: Net inflow of 65.5 million from institutional investors, with outflows from speculative and retail investors [3]